Heather L Rusch1,2, Pedro Guardado1, Tristin Baxter3, Vincent Mysliwiec3, Jessica M Gill1. 1. National Institute of Nursing Research, National Institutes of Health, Bethesda, MD. 2. Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD. 3. Madigan Army Medical Center, Tacoma, WA.
Abstract
STUDY OBJECTIVES: One-third of deployed military personnel will be diagnosed with insomnia, placing them at high risk for comorbid depression, posttraumatic stress disorder (PTSD), and medical conditions. The disruption of trophic factors has been implicated in these comorbid conditions, which can impede postdeployment recovery. This study determined if improved sleep quality is associated with (1) reductions in depression and posttraumatic symptoms, as well as enrichments in health-related quality of life (HRQOL), and (2) changes in plasma concentrations of brain derived neurotrophic factor (BDNF) and insulin-like growth factor-1 (IGF-1). METHODS: Forty-four military personnel diagnosed with insomnia underwent clinical evaluations and blood draws at pretreatment and at posttreatment following cognitive behavioral therapy for insomnia and automatic positive airway pressure treatment. Participants were classified as sleep improved (n = 28) or sleep declined (n = 16) based on their change in pretreatment to posttreatment Pittsburgh Sleep Quality Index (PSQI) score. Both groups were compared on outcomes of depression, PTSD, HRQOL, BDNF, and IGF-1. RESULTS: Paired t-tests of the sleep improved group revealed significant declines in depression (p = 0.005) and posttraumatic arousal (p = 0.006) symptoms, and a significant increase in concentrations of IGF-1 (p = 0.009). The sleep declined group had no relevant change in psychiatric symptoms or trophic factors, and had further declines on five of eight dimensions of HRQOL. Between-group change score differences were significant at p < 0.05. CONCLUSIONS: These findings suggest that interventions, which successfully improve sleep quality, are an effective means to reduce the depression and posttraumatic arousal symptoms common to military personnel, as well as increase protective trophic factors implicated in these conditions.
STUDY OBJECTIVES: One-third of deployed military personnel will be diagnosed with insomnia, placing them at high risk for comorbid depression, posttraumatic stress disorder (PTSD), and medical conditions. The disruption of trophic factors has been implicated in these comorbid conditions, which can impede postdeployment recovery. This study determined if improved sleep quality is associated with (1) reductions in depression and posttraumatic symptoms, as well as enrichments in health-related quality of life (HRQOL), and (2) changes in plasma concentrations of brain derived neurotrophic factor (BDNF) and insulin-like growth factor-1 (IGF-1). METHODS: Forty-four military personnel diagnosed with insomnia underwent clinical evaluations and blood draws at pretreatment and at posttreatment following cognitive behavioral therapy for insomnia and automatic positive airway pressure treatment. Participants were classified as sleep improved (n = 28) or sleep declined (n = 16) based on their change in pretreatment to posttreatment Pittsburgh Sleep Quality Index (PSQI) score. Both groups were compared on outcomes of depression, PTSD, HRQOL, BDNF, and IGF-1. RESULTS: Paired t-tests of the sleep improved group revealed significant declines in depression (p = 0.005) and posttraumatic arousal (p = 0.006) symptoms, and a significant increase in concentrations of IGF-1 (p = 0.009). The sleep declined group had no relevant change in psychiatric symptoms or trophic factors, and had further declines on five of eight dimensions of HRQOL. Between-group change score differences were significant at p < 0.05. CONCLUSIONS: These findings suggest that interventions, which successfully improve sleep quality, are an effective means to reduce the depression and posttraumatic arousal symptoms common to military personnel, as well as increase protective trophic factors implicated in these conditions.
Authors: Claudia Schilling; Werner F Blum; Isabella Heuser; Georgios Paslakis; Stefan A Wudy; Michael Deuschle Journal: J Clin Psychopharmacol Date: 2011-06 Impact factor: 3.153
Authors: Omer Bonne; Jessica Mary Gill; David A Luckenbaugh; Carlos Collins; Michael J Owens; Salvadore Alesci; Alexander Neumeister; Peixiong Yuan; Becky Kinkead; Huesseni K Manji; Dennis S Charney; Meena Vythilingam Journal: J Clin Psychiatry Date: 2010-12-28 Impact factor: 4.384
Authors: Heidi Terrio; Lisa A Brenner; Brian J Ivins; John M Cho; Katherine Helmick; Karen Schwab; Katherine Scally; Rick Bretthauer; Deborah Warden Journal: J Head Trauma Rehabil Date: 2009 Jan-Feb Impact factor: 2.710
Authors: Robert H Pietrzak; Douglas C Johnson; Marc B Goldstein; James C Malley; Steven M Southwick Journal: Depress Anxiety Date: 2009 Impact factor: 6.505
Authors: Heather L Rusch; Michael Rosario; Lisa M Levison; Anlys Olivera; Whitney S Livingston; Tianxia Wu; Jessica M Gill Journal: Ann N Y Acad Sci Date: 2018-12-21 Impact factor: 5.691
Authors: Heather L Rusch; Jeffrey Robinson; Sijung Yun; Nicole D Osier; Christiana Martin; Chris R Brewin; Jessica M Gill Journal: Brain Behav Immun Date: 2019-04-27 Impact factor: 7.217
Authors: Kevin M Swift; Connie L Thomas; Thomas J Balkin; Emily G Lowery-Gionta; Liana M Matson Journal: J Clin Sleep Med Date: 2022-09-01 Impact factor: 4.324
Authors: Anna S Ord; Erica L Epstein; Elizabeth R Shull; Katherine H Taber; Sarah L Martindale; Jared A Rowland Journal: Rehabil Psychol Date: 2022-04-14